Unsupervised machine learning reveals risk stratifying glioblastoma tumor cells.

Journal: eLife
PMID:

Abstract

A goal of cancer research is to reveal cell subsets linked to continuous clinical outcomes to generate new therapeutic and biomarker hypotheses. We introduce a machine learning algorithm, Risk Assessment Population IDentification (RAPID), that is unsupervised and automated, identifies phenotypically distinct cell populations, and determines whether these populations stratify patient survival. With a pilot mass cytometry dataset of 2 million cells from 28 glioblastomas, RAPID identified tumor cells whose abundance independently and continuously stratified patient survival. Statistical validation within the workflow included repeated runs of stochastic steps and cell subsampling. Biological validation used an orthogonal platform, immunohistochemistry, and a larger cohort of 73 glioblastoma patients to confirm the findings from the pilot cohort. RAPID was also validated to find known risk stratifying cells and features using published data from blood cancer. Thus, RAPID provides an automated, unsupervised approach for finding statistically and biologically significant cells using cytometry data from patient samples.

Authors

  • Nalin Leelatian
    Department of Cell and Developmental Biology, Vanderbilt University, Nashville, United States.
  • Justine Sinnaeve
    Department of Cell and Developmental Biology, Vanderbilt University, Nashville, United States.
  • Akshitkumar M Mistry
    Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN.
  • Sierra M Barone
    Department of Cell and Developmental Biology, Vanderbilt University, Nashville, United States.
  • Asa A Brockman
    Department of Cell and Developmental Biology, Vanderbilt University, Nashville, TN, USA.
  • Kirsten E Diggins
    Cancer Biology, Vanderbilt University School of Medicine, United States.
  • Allison R Greenplate
    Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, United States.
  • Kyle D Weaver
    Department of Neurosurgery, Vanderbilt University Medical Center, Vanderbilt University, Nashville, Tennessee, United States.
  • Reid C Thompson
    Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN, USA.
  • Lola B Chambless
    Department of Neurosurgery, Vanderbilt University Medical Center, Vanderbilt University, Nashville, Tennessee, United States.
  • Bret C Mobley
    Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN, USA.
  • Rebecca A Ihrie
    Department of Cell and Developmental Biology, Vanderbilt University, Nashville, TN, USA.
  • Jonathan M Irish
    Cancer Biology, Vanderbilt University School of Medicine, United States; Pathology, Microbiology and Immunology, Vanderbilt University School of Medicine, United States. Electronic address: jonathan.irish@vanderbilt.edu.